Management

Gad Berdugo, MSc. Eng., MBA
Gad Berdugo, MSc. Eng., MBA
CEO & Co-Founder

Gad is a seasoned biotechnology executive who brings more than 27 years of operational, business and corporate development, strategy and financial experience, mainly gained at Abbott, Baxter, Lazard and several emerging biotech companies. He holds a BSc. in Biotechnology from Imperial College London, a MSc. in Biochemical Engineering from University College London and an MBA from HEC Graduate School of Management.

Read Gad's full bio here...

image-2018-11-13-3.png
Anne (Annie) De Groot, MD
CSO (Interim) & Co-Founder

Anne De Groot is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She graduated from Smith College in 1978 and earned her medical degree at University of Chicago in 1983. After internal medical residency, she obtained advanced training in immunoinformatics and vaccinology with Michael Good, Russell Howard and Jay Berzofsky at the National Institutes of Health, and then returned for a fellowship in ID at New England Medical Center.​ 

Read Annie's full bio here...

image-2018-11-13.png
Dominique Bridon, PhD
CTO 

Dr. Dominique Bridon brings 30 years of executive and scientific leadership experience to the Epivax Oncology team. Most recently, he was Chief Executive officer at Biodesy, a company specialized in the detection of conformational changes.  He holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. 

Read Dominique's full bio here. . .

Michael Princiotta, PhD
VP, Research 

Michael Princiotta brings over 20 years experience in T cell immunology and antigen processing and presentation to Epivax Oncology. Most recently, he was Vice President of Research at Advaxis Immunotherapies where, as head of research, he oversaw the development of a personalized cancer vaccine from conception to Phase I clinical trial. Michael holds a Master of Science in Microbiology and Molecular Biology from the University of Central Florida and a PhD in Microbiology and Immunology from the University of Colorado Health Science Center in Denver Colorado. 

Read Michael's full bio here. . .

Headshot.png
Guilhem Richard, PhD
Lead Computational Immunologist 

Guilhem Richard brings immunoinformatics expertise to the EpiVax Oncology team. He has been a Computational Immunologist for over 4 years at EpiVax, focusing on refining its immuno-oncology platform. He holds a Master of Engineering in Bioinformatics and Modeling from the National Institute of Applied Science (INSA) of Lyon, France, and a Ph.D. in Bioinformatics from Boston University.

Read Guilhem's full bio here. . .

Board of Directors

Headshot.jpg
Daniel Adams, JD
Chairman 

Daniel Adams  is the Executive Chairman and Co‐Founder of NextWaveBio, a next‐generation biotechnology enterprise developing safer, more affordable pharmaceuticals. Mr. Adams served as CEO then as the Executive Chairman of Protein Sciences Corporation, a leader in developing and manufacturing vaccines, therapeutics and diagnostics, including Flublok®, a patented, first in class recombinant influenza vaccine, that received licensure from FDA in 2013. The Company was acquired by Sanofi for approximately $750 million. Previously Dan founded and managed several biotechnology companies including Biogen that achieved a combined value of well in excess of $60 billion. 

Read Dan's full bio here. . .

Gad Berdugo, 
MSc. Eng., MBA
 
CEO, EpiVax Oncology  
Anne (Annie)
De Groot, MD
 
CEO/CSO, EpiVax  
Bill Martin, 
BA
CTO/COO, EpiVax   

© Copyright Epivax Oncology 2020